Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC-002 in Relapsed/Refractory SCLC and LCNEC
NCT02500914Phase 1Terminated
- Sponsor
- Stemcentrx
- Start
- Jun 2015
- Primary completion
- Aug 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sc-002 in small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC), sponsored by Stemcentrx. Primary endpoints: Maximum Tolerated Dose at 6 months and Number of subjects with adverse events at 6 months. Started Jun 2015; status: terminated.
02
Drugs
sc-002
03
Conditions
small cell lung cancer (SCLC)large cell neuroendocrine carcinoma (LCNEC)
Beyond the preview
Go deeper on NCT02500914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02500914.